thalidomide has been researched along with Muscle Weakness in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity." | 9.12 | Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 7.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| "Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity." | 5.12 | Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 3.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| "Thalidomide therapy was initiated." | 2.61 | Nonresectable Thoracic Rosai-Dorfman Disease: A Case Report and Review of the Literature. ( Lin, CK; Tsai, YD, 2019) |
| "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects." | 1.33 | Thalidomide neuropathy in childhood. ( Chaitow, J; Darras, BT; Fleming, FJ; Jones, HR; Ryan, MM; Vytopil, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, CK | 1 |
| Tsai, YD | 1 |
| Jimenez-Zepeda, VH | 1 |
| Reece, DE | 1 |
| Trudel, S | 1 |
| Chen, C | 1 |
| Tiedemann, R | 1 |
| Kukreti, V | 1 |
| Fleming, FJ | 1 |
| Vytopil, M | 1 |
| Chaitow, J | 1 |
| Jones, HR | 1 |
| Darras, BT | 1 |
| Ryan, MM | 1 |
| Plasmati, R | 1 |
| Pastorelli, F | 1 |
| Cavo, M | 1 |
| Petracci, E | 1 |
| Zamagni, E | 1 |
| Tosi, P | 1 |
| Cangini, D | 1 |
| Tacchetti, P | 1 |
| Salvi, F | 1 |
| Bartolomei, I | 1 |
| Michelucci, R | 1 |
| Tassinari, CA | 1 |
1 review available for thalidomide and Muscle Weakness
| Article | Year |
|---|---|
Nonresectable Thoracic Rosai-Dorfman Disease: A Case Report and Review of the Literature.
Topics: Adult; Histiocytosis, Sinus; Humans; Immunosuppressive Agents; Low Back Pain; Lower Extremity; Male; | 2019 |
1 trial available for thalidomide and Muscle Weakness
| Article | Year |
|---|---|
Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Topics: Action Potentials; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Follow-Up St | 2007 |
2 other studies available for thalidomide and Muscle Weakness
| Article | Year |
|---|---|
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2013 |
Thalidomide neuropathy in childhood.
Topics: Action Potentials; Adolescent; Brain Neoplasms; Child; Crohn Disease; Disease Progression; Electromy | 2005 |